Immunization recommendations for adults with cancer.
OBJECTIVE
To review the published literature on immunizing nonbone marrow transplant adult cancer patients, summarize the findings, and make recommendations for the use of vaccines in this population.


METHODS
A search of MEDLINE and CancerLit was conducted (1966-June 2001) to find English-language clinical studies and review articles pertaining to immunization, vaccines, and cancer in humans. Recommendations of the Advisory Committee on Immunization Practices were used extensively. References of each identified article were subsequently reviewed for additional relevant articles.


METHODS
Representative epidemiologic reports, clinical trials, and recommendations of expert panels are summarized in this report. Relevant information was selected to describe the epidemiology of vaccine-preventable diseases, efficacy of the vaccines, and recommendations specific to adults with cancer.


RESULTS
In general, adults with cancer are at least at the same risk of infection with vaccine-preventable diseases as are healthy populations. Because of their compromised immune function, many patients who have undergone cancer treatment are specifically at increased risk of morbidity and mortality associated with measles and varicella infections. Asplenic patients with lymphoma are at increased risk of fulminant bacterial infections. Influenza infection is associated with significant morbidity in cancer patients. Although the protection conferred by immunization is lower in immunosuppressed patients with cancer, immunization with inactivated vaccines is indicated. Live vaccines should not be used except in very rare instances.


CONCLUSIONS
Immunization of adults with cancer is a critical component of their care. Although additional research is necessary, following established recommendations may protect individuals with malignancies from significant morbidity and mortality associated with vaccine-preventable diseases.
Arrowood
Jodi R
JR
Saint Joseph's Hospital, Marshfield, WI, USA.
Hayney
Mary S
MS
D000328:Adult; D000917:Antibody Formation; D002986:Clinical Trials as Topic; D003140:Communicable Disease Control / Q000379:methods*; D003141:Communicable Diseases / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*